-
Citi Raises TESARO Price Target 38%, Sees 16.3% Upside
Friday, July 1, 2016 - 4:27pm | 247Read More...Citi now sees 16.3 percent upside in the shares of TESARO Inc (NASDAQ: TSRO) following its price target increase to $90 from $65, as it is "now more confident about Niraparib approval in ovarian cancer and reimbursement." The 16.3 percent upside is based on the stock's June 29 closing price of $77....
-
Alexion Pharma Brexit Selloff Creates An Entry Point: Trading At 'Dark-Sky' Valuation
Monday, June 27, 2016 - 1:32pm | 242Read More...Since the United Kingdom voted to leave the European Union, Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)'s share price has dropped 10.77 percent. Citi's Take Citibank's Robyn Karnauskas upgraded Alexion Pharmaceuticals to Buy without changing her $154.00 price target, seeing Brexit as a "good entry...
-
Regeneron CEO And CFO Met With Citi: Here Are The Takeaways
Thursday, June 23, 2016 - 10:37am | 270Read More...Citi’s Robyn Karnauskas mentioned three key takeaways after meeting with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) management - CEO Leonard Schleifer, CFO Bob Landry and Director IR Manisha Narasimhan. These were: Injunction decision could come by late fall, while company believes...
-
Lingo Failure Leads Citi To Downgrade Biogen
Wednesday, June 8, 2016 - 10:03am | 261Read More...Biogen Inc (NASDAQ: BIIB) announced that anti-Lingo failed both the primary and the secondary endpoints in its Phase 2 RRMS trial. Citi’s Robyn Karnauskas downgraded the rating on the company from Buy to Neutral, while lowering the price target from $345 to $295. Lingo Failure “While...
-
Solid Potential For Gilead To Beat Estimates And Raise Guidance: Here's How
Tuesday, May 31, 2016 - 9:56am | 585Read More...Citi expects Gilead Sciences, Inc. (NASDAQ: GILD) to report a beat and raise second-quarter, as it sees about $280 million upside to consensus second-quarter sales and about $500 million upside to consensus 2016 sales. Expectations The Street expects Gilead to earn $2.99 a share on revenue of $7.75...
-
Citi Surprised, Confused Amid Report Biogen May Divest Hemophilia Unit
Monday, April 11, 2016 - 8:16am | 253Read More...Reuters reported on Friday that Biogen Inc (NASDAQ: BIIB) is exploring the sale of its hemophilia business. Citi’s Robyn Karnauskas maintained a Buy rating for the company, with a price target of $345, saying that the news is both “surprising and confusing,” since previously the...
-
Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover
Thursday, February 25, 2016 - 9:51am | 546Read More...Citi’s Robyn Karnauskas said that while the fundamentals of large-cap biotech stocks remained intact, a full recovery could take time. He added, “We favor catalyst rich growth stocks in the recovery cycle [over value stocks].” Analyst Robyn Karnauskas initiated coverage of the...
-
BioMarin's Results Are In: What Do They Mean?
Thursday, June 18, 2015 - 10:31am | 441Read More...Encouraging early results from a trial of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) dwarfism treatment sent the company's shares higher Thursday while analysts boosted their targets. Shares changed hands recently at $138.50, up 12 percent. BioMarin said a trial of its vosoritide drug in...
-
Deutsche Sees Cancer Treatment Home Run At Infinity Pharmaceuticals
Thursday, May 7, 2015 - 4:52pm | 225Read More...Infinity Pharmaceuticals Inc.'s (NASDAQ: INFI) blood cancer drug Duvelisib could hit annual sales of $1.2 billion by capturing even a small share of the market, an analyst said Thursday. Deutsche Bank's Robyn Karnauskas launched coverage on Infinity with a $20 target and said its partnership with...
-
This Data Offers Insight Into Gilead Sales
Wednesday, April 8, 2015 - 12:44pm | 587Read More...Gilead Sciences, Inc. (NASDAQ: GILD) received new data from IMS Health about the breakdown of its drug prescriptions. Gilead is most known for its hepatitis C medications, Harvoni and Sovaldi. IMS prescription data breaks down how many people are receiving which drug prescriptions in more than...
-
Gilead Alert: What Deutsche Bank Is Saying
Monday, April 6, 2015 - 12:36pm | 355Read More...Deutsche Bank commented on Gilead Sciences, Inc. (NASDAQ: GILD) Monday and maintained a Buy rating with a $125 price target. Analysts, led by Robyn Karnauskas, noted that the firm's survey indicated that the reimbursement process was easing with more previously undiagnosed patients getting...
-
Why BioMarin Pharmaceutical Is Surging
Friday, March 27, 2015 - 11:22am | 275Read More...BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) jumped over 14 percent on Friday, as a buyout rumor surfaced just ahead of an apparently routine conference call with analysts concerning its developmental drug programs. Separately, Deutsche Bank's Robyn Karnauskas published a note on Friday...
-
Analyst: Alexion Pharmaceuticals Pipeline Is Undervalued
Wednesday, March 11, 2015 - 4:55pm | 210Read More...Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is getting insufficient credit from investors for its development pipeline, an analyst said Wednesday. The company's sole commercial product, Soliris, is approved for treating two rare blood disorders and produced sales last year of about $2.23...
-
Analysts Mixed On Premium For Pharmacyclics
Thursday, March 5, 2015 - 5:48pm | 367Read More...AbbVie Inc (NYSE: ABBV) $21 billion deal to acquire Pharmacyclics, Inc. (NASDAQ: PCYC) Thursday drew mixed reviews from analysts and a thumbs down in the stock market. Shares of AbbVie closed down more than 5 percent at $56.83. The price paid by AbbVie may be a sign of a "desperation...
-
Deutsche Bank Comments On Concerns Over Consensus Estimates For AbbVie And Gilead Sciences
Wednesday, January 21, 2015 - 5:27pm | 210Read More...Deutsche Bank commented on AbbVie Inc (NYSE: ABBV) and Gilead Sciences, Inc. (NASDAQ: GILD) Wednesday and felt that consensus may be too high on both companies. Analyst Robyn Karnauskas commented that "the key question we are getting from investors is if ABBV 2015 consensus is too high for...
